Ads
related to: high risk maternal fetal medicine
Search results
Results From The WOW.Com Content Network
Maternal–fetal medicine (MFM), also known as perinatology, is a branch of medicine that focuses on managing health concerns of the mother and fetus prior to, during, and shortly after pregnancy. Maternal–fetal medicine specialists are physicians who subspecialize within the field of obstetrics. [ 1 ]
A maternal-fetal medicine specialist or MFM is an Obstetrician trained in managing complex and high-risk pregnancies. [58] They are also known as Perinatologists or High-Risk OBGYNs. [59] Complex Family Planning Specialist. This is an OBGYN trained in managing pregnancy in individuals or fetuses with complex health conditions.
Avoidance actions like vaccines and strict infectious control protocols can be given priority in the policies aimed at limiting the risk of transmission among high-risk populations. In addition, it is early diagnosis and management of maternal infections are among the main methods to flatline vertical transmission and fetal aberrations.
Board certified maternal-fetal medicine physicians have an additional two to three years training in maternal-fetal medicine (MFM) and are involved in the latest advancements in maternal and fetal care. Because of their additional training, MFM's are considered high-risk pregnancy experts.
Maternal-fetal medicine: an obstetrical subspecialty, sometimes referred to as perinatology, that focuses on the medical and surgical management of high-risk pregnancies and surgery on the fetus with the goal of reducing morbidity and mortality.
Dr. Marlo Vernon at the the Maternal Health Farmacy in Augusta, Ga., May 7, 2024. According to the Centers for Disease Control and Prevention, the state of Georgia has one of the worst maternal ...
This test tells whether there are antibodies in the maternal plasma. If positive, the antibody is identified and given a titer. Titers of 1:4 or higher is considered critical for Kell (compared to 1:16 for most other antibodies) and is considered to confer a high risk of fetal anemia. [17]
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM).